On toxic poisoning by a cross-polarizing substance Dotarem following a medical examination in Greece  

The petitioner claims that the medicinal product Dotarem (a gadolinium-based contrast imaging agent), which is marketed in the European Union and used during medical examination procedures with Magnetic Resonance Imaging (MRI), caused him serious toxic poisoning. In particular, he claims that the medication was not removed by the kidneys within one week, as indicated on the medication’s instructions, and that 3.5 months after he was administered the medication, it was diagnosed that the amount of gadolinium that exits from his urine is three times the maximum acceptable limit. He also claims that, as a result, he developed systemic fibrosis throughout his body with obvious damage to the skin, eyes, face, and severe physical exhaustion. He calls for all the necessary measures to be taken to ensure the public health of EU citizens and for him to be compensated by the Dotarem manufacturer and to be admitted in a specialized EU clinic for the removal of the gadolinium from his body.